Renowned economist Richard Werner challenges traditional views on banks, stating they have the unique power to create money.

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

FRANKFURT: European shares logged their biggest daily rise in over two weeks on Thursday, boosted by financial ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side ...

Plus: Trump demands Intel CEO resign over links to China; Firefly Aerospace jumps in Nasdaq debut after oversubscribed IPO; OpenAI releases GPT-5 with PhD smarts for all users.

The company said it plans to develop its new Chai‑2 platform to design, from square one, completely new antibodies for ...

After a rough reception and a rebrand to support users of GLP-1 drugs, Peoplehood is selling its assets to WeightWatchers.

How could higher U.S. tariffs on Indian pharmaceutical products impact drug stocks? Seeking Alpha analysts weigh in. Read ...

Elanco beats Q2 expectations and raises 2025 guidance as strong Pet Health sales and FX tailwinds offset tariff and ...

This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members ...

Results involving the highest dose of orforglipron disappointed investors — but still bring the drug a step closer to ...